Name of the Issue: Lauras Labs Limited. 1 Type of Issue Initial Public Offer. 2 Issue Size (Rs. Mn) 13,305.10

Size: px
Start display at page:

Download "Name of the Issue: Lauras Labs Limited. 1 Type of Issue Initial Public Offer. 2 Issue Size (Rs. Mn) 13,305.10"

Transcription

1 Name of the Issue: 1 Type of Issue Initial Public Offer 2 Issue Size (Rs. Mn) 13, *Source: Prospectus dated December 12, Grade of issue along with name of the rating agency Name Grade NA NA 4 Subscription Level (Number of times) 3.50 * Figure is after technical rejections Source: Basis of allotment 5 QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges Particulars %age (i) On Allotment ** 4.74% (ii) at the end of the 1st Quarter immediately after the listing of the issue (December 31, 2016)** (iii) at the end of 1st FY (March 31, 2017)** 53.78% (iv) at the end of 2nd FY (March 31, 2018) ** 50.64% (v) at the end of 3rd FY (March 31, 2019) * * QIB Holding not disclosed as reporting for relevant period has not been completed. Source: ** Basis of Allotment 6 Financials of the issuer (Rs. Million) 1st FY (March 2nd FY (March 3rd FY (March Parameters 31,2017) 31,2018) 31,2019) * Income from operations 19,315 20,690 Not Available Net Profit for the period 1,913 1,676 Not Available Paid-up equity share capital 1,058 1,060 Not Available Reserves 1,225 13,766 Not Available * Financials not available as reporting for the relevant years has not been completed. Source: Company filings 53.46% N.A.

2 7 Trading Status The equity shares of are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") (and together with BSE the "Stock Exchanges") The equity shares have not been suspended or delisted. Particulars (i) at the end of 1st FY (March 31, 2017) (ii) at the end of 2nd FY (March 31, 2018) * Status Frequentrly traded Frequentrly traded (iii) at the end of 3rd FY (March 31, 2019) * Not Available * Trading status not disclosed as the relevant fiscal years have not been completed. Source: Stock exchange data. 8 Change in Directors of Issuer from the disclosures in the offer document Particulars Name of Director Appointed / Resigned (i) at the end of 1st FY (March 31, 2017) Massimo Venuti Appointed Asanka Rodrigo Resigned (ii) at the end of 2nd FY (March 31, 2018) Rajesh Dugar Resigned Dr. Srihari Raju Kalidindi Dr. Venkata Lakshmana Rao Chunduru Resigned Appointed (iii) at the end of 3rd FY (March 31, 2019) * Not Available Not Available * Changes in Directors of Issuer not updated as the relevant financial years have not been completed 9 Status of implementation of project/ commencement of commercial production (i) as disclosed in the offer document (ii) Actual implementation (iii) Reasons for delay in implementation, if any

3 10 Status of utilization of issue proceeds (i) As disclosed in the offer document (Rs. Million) Particulars Total estimated fund requirement Fiscal 2017 Fiscal 2018 Prepayment of term loans 2,263 2,263 - General Corporate Purposes Note: As disclosed in the prospectus (ii) Actual utilization Particulars Total estimated fund requirement Fiscal 2017 Fiscal 2018 Prepayment of term loans 2,263 2,263 - General Corporate Purposes (iii) Reasons for deviation, if any 11 Comments of monitoring agency, if applicable (i) Comments on use of funds (ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document (iii) Any other reservations expressed by the monitoring agency about the end use of funds

4 12 Pricing Data Designated Stock Exchange NSE Issue Price (Rs.) Listing Date 19-Dec-16 Price parameters At close of listing day December 19, 2016 Close of 30th calendar day from listing day Close of 90th calendar day from listing day As at the end of the 1st FY after the listing of the issue ( 31st March,2017) Closing price High Low Market Price CNX NIFTY , , , , ,546.5 Price parameters As at the end of the 2nd FY after the listing of the issue ( 31st March,2018) (1) Closing price High Low Closing price High Low Market Price Not Available Not Available Not Available CNX NIFTY 10, , ,103.5 Not Available Not Available Not Available * Being index of BSE, the designated stock exchange (1) The pricing data is not disclosed as the relevant fiscal years have not been completed As at the end of the 3rd FY after the listing of the issue ( 31st March,2019) (1)

5 13 Basis for Issue Price Accounting ratio EPS (Basic) P/E As disclosed in offer document* At the end of 1st FY (March 31,2017)** At the end of 1st FY (March 31,2018)*** At the end of 1st FY (March 31,2019)*** Not Available Not Available Not Available Not Available RoNW 15.57% 14.30% 11.30% Not Available 30.37% 19.85% 17.77% Not Available NAV per share Not Available Not Available Notes * Sourced and caculated as per Prospectus dated December 12, 2016 and Company filings uploaded on the stock exchange websites ***Not available as the relevant fiscal years have not been completed 14 Any other material information ** Peer groups include Divis Laboratories Ltd. amd Aurobindo Pharma Limited Particulars Date Remarks Laurus Labs Ltd has informed BSE that consequent to listing of equity shares of the Company on the Stock Exchanges 29-Dec-16 Laurus Labs Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 09,2017, inter alia, to consider and approve the Unaudited Financial Results of the Companyfor the Quarter and 9 months period ended December 31, Further, the Company s trading window for dealing in securities by the Directors and Designated Persons shall be closed from February 03, 2017 to February 11, 2017 (both days inclusive) Mr. Frank J Wright (DIN ), the Director of the Company, has tendered his resignation from the Board of the Company with effect from March 31, A copy of the said resignation letter received by the Company is attached for your information and records Company's pharmaceutical formulation & marketing partner Natco Pharma Ltd ('Natco') has launched the generic version of Sofosbuvir 400 mg/ Velpatasvir 100 mg fixed dose combination in India based on an API supplied by the Company The API facility of the Unit 2 has completed successful USFDA inspection without any 483 and the formulations unit in the same facility received EIR (Establishment Inspection Report) on May 18, 2017 Laurus Labs receives the EIR from USFDA, and also successfully completes the German Regulatory Authority for Unit 2 and WHO inspections for Units 1 & 3. 2-Feb Mar-17 8-May May Sep-17

6 Particulars Date Remarks Laurus Labs Limited has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (US FDA) for its Unit 1& 3, located at Parawada, Visakhapatnam, for the inspection conducted in August Nov-17 1-Mar-18 USFDA audit successfully completed without observations - ZERO 483 for its Unit 2 (formulations unit). The inspection was carried out from 26th Feb st March Laurus Labs Ltd has also received its maiden Approval from United States Food and Drug Administration (U.S FDA) for Tenofovir Disoproxil Fumarate Tablets 300mg. Tenofovir Disoproxil Fumarate Tablets 300mg is therapeutically equivalent to VIREAD Tablets 300mg of Gilead Science Ltd. (GILEAD). Tenofovir Disoproxil Fumarate Tablets 300mg is used for treatment of HIV-1 infection in adults and paediatric patients 2 years of age and older Note: For further updates and information, please refer stock exchange websites i.e. and

7 DISCLAIMER: The information disclosed on this website has been uploaded by Citigroup Global Markets India Private Limited ("Citi") solely pursuant to the requirements of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012 (the Circular ) for the limited purpose of the Circular, without having regard to specific objectives, suitability, financial situations or the needs of any particular person, and does not constitute any recommendation, and should not be construed as an offer to sell or the solicitation of an offer to buy, purchase or subscribe to any securities mentioned herein. Neither this information, nor anything else contained on this website, shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. Nothing in this information is intended by Citi to be construed as legal, regulatory, accounting, tax or other advice. Past performance is not necessarily a guide for future performance. The information disclosed on this website has been collated from different sources, including, but not limited to, information obtained from the websites of the BSE Limited ( The National Stock Exchange of India Limited ( websites of the respective issuer companies, annual reports of the issuer companies, certain databases such as and post issue reports filed with Securities and Exchange Board of India. Neither Citi, its affiliates nor any of their respective directors, employees, agents or representatives makes any implicit or explicit representation or warranty regarding the accuracy or completeness of the information or accepts or assumes any responsibility for the accuracy or completeness of the information or any loss whether direct or indirect, incidental, special or consequential that may arise from or in connection with the use of this information or otherwise. The information disclosed on this website is updated as of June 12, Citi does not undertake to update the information contained herein except as required by applicable law or regulation.

N.A. 2nd FY (March 31, 2020) * Page 1 of 5

N.A. 2nd FY (March 31, 2020) * Page 1 of 5 Name of the Issue: TCNS Clothing Co. Limited 1 Type of Issue Initial Public Offer 2 Issue Size (Rs. Mn) 11,251.25 *Source: Prospectus dated July 24, 2018 3 Grade of issue along with name of the rating

More information

Name of the Issue: SBI Life Insurance Company Limited. 1 Type of Issue Initial Public Offer. 2 Issue Size (Rs. Cr)* 8,388.73

Name of the Issue: SBI Life Insurance Company Limited. 1 Type of Issue Initial Public Offer. 2 Issue Size (Rs. Cr)* 8,388.73 Name of the Issue: SBI Life Limited 1 Type of Issue Initial Public Offer 2 Issue Size (Rs. Cr)* 8,388.73 Fresh Issue Size (Rs. Cr) Nil Offer for Sale Component (Rs. Cr) 8,388.73 *Source: Final Post Issue

More information

InterGlobe Aviation Ltd. Track Record

InterGlobe Aviation Ltd. Track Record 1 Type of Issue IPO 2 Issue Size (Rs. mn) 30,171.00 Source: Basis of Allotment 3 Grade of issue along with name of the rating agency Name Not applicable Grade Not applicable 4 Subscription Level (Number

More information

1 Type of Issue (IPO / FPO) IPO 2 Issue Size (Rs. Cr) Source: Prospectus dated March 28, 2016

1 Type of Issue (IPO / FPO) IPO 2 Issue Size (Rs. Cr) Source: Prospectus dated March 28, 2016 Name of the Issue: Infibeam Incorporation Limited Last updated on April 12, 2016 1 Type of Issue (IPO / FPO) IPO 2 Issue Size (Rs. Cr) 450.00 Source: Prospectus dated March 28, 2016 3 Grade of issue along

More information

Repco Home Finance Limited. Last updated on 31-Dec Name of the Issue:

Repco Home Finance Limited. Last updated on 31-Dec Name of the Issue: Name of the Issue: Repco Home Last updated on 31-Dec-2013 1 Type of Issue (IPO / FPO) IPO 2 Issue Size (Rs. Cr) 270.23 3 Grade of issue along with name of the rating agency Name ICRA Grade 3 4 Subscription

More information

Not Applicable. 2nd FY (March 31, 2020)*

Not Applicable. 2nd FY (March 31, 2020)* Name of the IndoStar Capital Finance Limited Last updated on 21-May-18 1 Type of Issue (IPO / FPO) IPO 2 Issue Size (Rs. Cr)* 1,844.00 - Fresh Issue Size (Rs. Cr) 700.00 - Offer for Sale Component (Rs.

More information

Reliance Nippon Life Asset Management Limited - Track Record

Reliance Nippon Life Asset Management Limited - Track Record Name of the issue: Reliance Nippon Life Asset Management Limited 1 Type of issue (IPO/ FPO) Initial Public Offer ("IPO") 2 Issue size (Rs crore) 1,542.24 3 Grade of issue along with name of the rating

More information

TRACK RECORD OF THE PUBLIC ISSUES. HDFC Standard Life Insurance Company Limited. 2. Issue Size (Rs. Cr) INR 8, Cr.

TRACK RECORD OF THE PUBLIC ISSUES. HDFC Standard Life Insurance Company Limited. 2. Issue Size (Rs. Cr) INR 8, Cr. TRACK RECORD OF THE PUBLIC ISSUES Name of the Issue: HDFC Standard Life 1. Type of Issue (IPO/FPO) IPO 2. Issue Size (Rs. Cr) INR 8,695.00 Cr 3. Grade of issue along with name of the rating agency Name

More information

5) QIB holding (as a % of total outstanding capital) as disclosed to stock exchanges. Not Applicable

5) QIB holding (as a % of total outstanding capital) as disclosed to stock exchanges. Not Applicable Name of the Issue: SRG Securities Finance Ltd. (the Company ) 1) Type of issue (IPO/ FPO) : Initial Public Offer (IPO) 2) Issue size (Rs crore): Rs. 5.016 Crore 3) Grade of issue along with name of the

More information

1 Type of Issue (IPO/FPO) IPO. 2 Issue Size (Rs. Cr) Grade of issue alongwith name of the rating agency

1 Type of Issue (IPO/FPO) IPO. 2 Issue Size (Rs. Cr) Grade of issue alongwith name of the rating agency Name of the Issue: PTC India Financial Services Limited 1 Type of Issue (IPO/FPO) IPO 2 Issue Size (Rs. Cr) 433.48 3 Grade of issue alongwith name of the rating agency Credit Analysis & Research Name ICRA

More information

Reliance Nippon Life Asset Management Limited - Track Record

Reliance Nippon Life Asset Management Limited - Track Record Name of the issue: Reliance Nippon Life Asset Management Limited 1 Type of issue (IPO/ FPO) Initial Public Offer ("IPO") 2 Issue size (Rs crore) 1,542.24 3 Grade of issue along with name of the rating

More information

ICICI Prudential Life Insurance Company Limited - Track Record

ICICI Prudential Life Insurance Company Limited - Track Record Name of the issue: ICICI Prudential Life Insurance Company Limited 1 Type of issue (IPO/ FPO) Initial Public Offer ("IPO") 2 Issue size (Rs crore) 6,056.79 3 Grade of issue alongwith name of the rating

More information

Page 1 of 5. Name of the Issuer: Shankara Building Products Limited ("Issuer") 1 Type of Issue Initial Public Offer

Page 1 of 5. Name of the Issuer: Shankara Building Products Limited (Issuer) 1 Type of Issue Initial Public Offer Name of the : Shankara Building Products Limited ("") 1 Type of Issue Initial Public Offer 2 Issue size (Rs. in crore) 345.00 Source: Prospectus dated March 27, 2017 3 Grade of Issue alongwith Name of

More information

5. QIB holding (as a % of total outstanding capital) as disclosed to stock exchanges

5. QIB holding (as a % of total outstanding capital) as disclosed to stock exchanges Name of the Issue: (the Company ) 1. Type of issue (IPO/ FPO): Initial Public Offer (IPO) on SME Platform 2. Issue size (Rs crore): Rs. 4.53 crores Source: Prospectus 3. Grade of issue along with name

More information

Prabhat Dairy Limited. Not Applicable. 2nd FY (March 31, 2017) 1st FY (March 31, 2016)

Prabhat Dairy Limited. Not Applicable. 2nd FY (March 31, 2017) 1st FY (March 31, 2016) Name of the Issue: Prabhat Dairy Limited 1 Type of Issue (IPO / FPO) IPO 2 Issue Size (Rs. Cr) 356.19 Source: Prospectus dated September 10, 2015 3 Grade of issue along with name of the rating agency Name

More information

DLF Limited - Track Record

DLF Limited - Track Record Name of the issue: DLF Limited 1 Type of issue (IPO/ FPO) Institutional Placement Programme ("IPP") 2 Issue size (Rs crore) 1,863.42 3 Grade of issue alongwith name of the rating agency Not Applicable

More information

1 Type of Issue (IPO / FPO) IPO. 2 Issue Size (Rs. Cr) Fresh Issue Size (Rs. Cr) Offer for Sale Component (Rs. Cr) 396.

1 Type of Issue (IPO / FPO) IPO. 2 Issue Size (Rs. Cr) Fresh Issue Size (Rs. Cr) Offer for Sale Component (Rs. Cr) 396. Name of the HEALTHCARE GLOBAL ENTERPRISES LIMITED 1 Type of Issue (IPO / FPO) IPO 2 Issue Size (Rs. Cr) 649.64 - Fresh Issue Size (Rs. Cr) 252.88 - Offer for Sale Component (Rs. Cr) 396.76 Source: Prospectus

More information

Name of the issuer: PNB Housing Finance Limited (the Company / the Issuer ) 1. Type of issue (IPO/ FPO) Initial Public Offering (IPO)

Name of the issuer: PNB Housing Finance Limited (the Company / the Issuer ) 1. Type of issue (IPO/ FPO) Initial Public Offering (IPO) Name of the issuer: PNB Housing Finance Limited (the Company / the Issuer ) 1. Type of issue (IPO/ FPO) Initial Public Offering (IPO) 2. Issue size (Rs crore / Rs mm) Rs. 3000.00 crores / Rs. 30,000.00

More information

Name of the issue: Infrastructure Development Finance Company Limited

Name of the issue: Infrastructure Development Finance Company Limited Name of the issue: Infrastructure Development Finance Company Limited 1 2 3 Type of issue: Public Issue by Infrastructure Development Finance Company Limited ( Company Or Issuer ) of long term infrastructure

More information

6. Financials of the issuer (as per the annual financial results submitted to stock exchanges):

6. Financials of the issuer (as per the annual financial results submitted to stock exchanges): 1. Type of Issue: IPO 2. Issue size (INR crore): 1,542.24 3. Grade of issue along with name of the rating agency: i. Name: Not Applicable ii. Grade: Not Applicable 4. Subscription Level (Number of times):

More information

Tata Steel Track Record. Page 1 of 5

Tata Steel Track Record. Page 1 of 5 Track Record Limited Updated Till August 17, 2012 1 Type of Issue FPO 2 Issue Size (Rs. Cr) 3,477 3 Grade of issue alongwith name of the rating agency NA for FPO 4 Subscription Level (Number of times)

More information

1 Type of Issue (IPO/FPO) IPO. 2 Issue Size (Rs. Cr) *Source: Final Post Issue Monitoring Report dated August 31, *

1 Type of Issue (IPO/FPO) IPO. 2 Issue Size (Rs. Cr) *Source: Final Post Issue Monitoring Report dated August 31, * Name of the Issue: 1 Type of Issue (IPO/FPO) IPO 2 Issue Size (Rs. Cr) *Source: Final Post Issue Monitoring Report dated August 31, 2015 273.216* 3 Grade of issue along with name of the rating agency Name

More information

5 QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges. Particulars

5 QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges. Particulars Name of the BANDHAN BANK LIMITED 1 Type of Issue (IPO / FPO) IPO 2 Issue Size (Rs. Cr) 4,473.02 - Fresh Issue Size (Rs. Cr) 3,662.40 - Offer for Sale Component (Rs. Cr) 810.62 3 Grade of issue along with

More information

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS. ICICI Prudential Life Insurance Company Limited

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS. ICICI Prudential Life Insurance Company Limited TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS Name of the Issue: ICICI Prudential Life Insurance Company Limited 1. Type of Issue (IPO/FPO) IPO 2. Issue

More information

GUJARAT PIPAVAV PORT LIMITED

GUJARAT PIPAVAV PORT LIMITED GUJARAT PIPAVAV PORT LIMITED DISCLOSURE OF TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY MERCHANT BANKERS (In terms of Circular No. CIR/MIRSD/1/2012 dated January 10, 2012) Sr. No. Particulars 1) Type of

More information

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS. Central Depository Services (India) Limited

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS. Central Depository Services (India) Limited TRACK RECORD OF THE PUBLIC ISSUES MAGED BY THE MERCHANT BANKER IN THE LAST 3 FINCIAL YEARS Name of the Issue: Central Depository Services (India) Limited 1. Type of Issue (IPO/FPO) IPO 2. Issue Size (Rs.

More information

NAME OF THE ISSUE: GANESH FILMS INDIA LIMITED. 1 Type of issue (IPO/FPO) : Initial Public Offer (IPO) on SME Platform N.A

NAME OF THE ISSUE: GANESH FILMS INDIA LIMITED. 1 Type of issue (IPO/FPO) : Initial Public Offer (IPO) on SME Platform N.A NAME OF THE ISSUE GANESH FILMS INDIA LIMITED 1 Type of issue (IPO/FPO) Initial Public Offer (IPO) on SME Platform 2 Issue size (Rs. Lakhs) Rs. 842.24 Lakhs 3 Grade of issue along with name of rating agency

More information

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS. HDFC Standard Life Insurance Company Limited

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS. HDFC Standard Life Insurance Company Limited TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS Name of the Issue: HDFC Standard Life Insurance Company Limited 1. Type of Issue (IPO/FPO) IPO 2. Issue Size

More information

Name of the Issue: Coal India Limited (the Company ) 1. Type of Issue (IPO/FPO) Initial Public Offering (IPO)

Name of the Issue: Coal India Limited (the Company ) 1. Type of Issue (IPO/FPO) Initial Public Offering (IPO) Name of the Issue: Coal India Limited (the Company ) 1. Type of Issue (IPO/FPO) Initial Public Offering (IPO) 2. Issue Size (Rs. Cr) Rs. 15,199.44 crore (after adjusting for Retail & Employee Discount)

More information

Name of the issuer: PNB Housing Finance Limited (the Company / the Issuer ) 1. Type of issue (IPO/ FPO) Initial Public Offering (IPO)

Name of the issuer: PNB Housing Finance Limited (the Company / the Issuer ) 1. Type of issue (IPO/ FPO) Initial Public Offering (IPO) Name of the issuer: PNB Housing Finance Limited (the Company / the Issuer ) 1. Type of issue (IPO/ FPO) Initial Public Offering (IPO) 2. Issue size (Rs crore / Rs mm) Rs. 3000.00 crores / Rs. 30,000.00

More information

S. No. Name of the issue: MUTHOOT FINANCE LIMITED Issue opening date: August 23, Last updated on: March 31, 2014

S. No. Name of the issue: MUTHOOT FINANCE LIMITED Issue opening date: August 23, Last updated on: March 31, 2014 S. No. 1 2 Name of the issue: MUTHOOT FINANCE LIMITED Issue opening date: August 23, 2011 Last updated on: March 31, 2014 Type of Issue: PUBLIC ISSUE OF SECURED NON CONVERTIBLE DEBENTURES OF FACE VALUE

More information

Name of the issue: RBL BANK LIMITED

Name of the issue: RBL BANK LIMITED Name of the issue: RBL BANK LIMITED 1 Type of issue (IPO/ FPO) IPO 2 Issue size (Rs Crores) 1212.97 3 Grade of issue alongwith name of the rating agency Name Grade 4 Subscription level (number of times)

More information

Name of the Issue: DLF Limited. Institutional Placement Programme. 1 Type of Issue. 2 Issue Size (Rs. Mn) 18,634.24

Name of the Issue: DLF Limited. Institutional Placement Programme. 1 Type of Issue. 2 Issue Size (Rs. Mn) 18,634.24 Name of the Issue: DLF Limited 1 Type of Issue Institutional Placement Programme 2 Issue Size (Rs. Mn) 18,634.24 Source: Final Post Issue Monitoring Report dated May 27,2013 3 Grade of issue along with

More information

Name of the Issue: Ujjivan Financial Services Limited. Updated till August 31, 2017, unless indicated otherwise. 1 Type of Issue IPO

Name of the Issue: Ujjivan Financial Services Limited. Updated till August 31, 2017, unless indicated otherwise. 1 Type of Issue IPO Name of the Issue: Ujjivan Financial Services Limited 1 Type of Issue IPO 2 Issue Size (Rs. Cr) 882.50 Source: Prospectus dated May 3, 2016 Note: In addition, the Company completed a Pre-IPO Placement

More information

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS Disclaimer This track record information has been uploaded by Goldman Sachs (India) Securities Private ("Goldman

More information

Name of the Issuer: TD Power Systems Limited. 1 Type of Issue (IPO/FPO) IPO. 2 Issue Size (Rs. Cr) 227

Name of the Issuer: TD Power Systems Limited. 1 Type of Issue (IPO/FPO) IPO. 2 Issue Size (Rs. Cr) 227 Name of the Issuer: TD Power Systems Limited 1 Type of Issue (IPO/FPO) IPO 2 Issue Size (Rs. Cr) 227 3 Grade of issue alongwith name of the rating agency Name Credit Analysis and Research Limited Grade

More information

Name of the Issue: Multi Commodity Exchange of India Limited Last updated on: 30-May-14

Name of the Issue: Multi Commodity Exchange of India Limited Last updated on: 30-May-14 Name of the Issue: Multi Commodity Exchange of India Limited Last updated on: 30-May-14 1 Type of Issue (IPO/FPO) IPO - Offer for sale 2 Offer Size (INR MM) 6,633.10 3 Grade of offer alongwith name of

More information

Name of the Issue:- RAJ OIL MILLS LIMITED Updated up to August 31, 2012

Name of the Issue:- RAJ OIL MILLS LIMITED Updated up to August 31, 2012 Name of the Issue:- RAJ OIL MILLS LIMITED Updated up to August 31, 2012 S.No Particulars Remarks 1 Type of issue (IPO/ FPO) IPO 2 Issue size Rs.114. 00 crores 3 Grade of issue alongwith name of the rating

More information

*The Company raised Rs. 10,000 crores in the Tranche 1 Issue.

*The Company raised Rs. 10,000 crores in the Tranche 1 Issue. TRACK RECORD OF THE PUBLIC ISSUES MAGED BY ICICI BANK LIMITED AS A MERCHANT BANKER IN CURRENT FINCIAL YEAR DEWAN HOUSING FINCE CORPORATION LIMITED 1. Type of Issue Public Issue by Dewan Housing Finance

More information

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS NATIONAL HIGHWAYS AUTHORITY OF INDIA

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS NATIONAL HIGHWAYS AUTHORITY OF INDIA TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS NATIONAL HIGHWAYS AUTHORITY OF INDIA 1. Type of issue PUBLIC ISSUE BY NATIONAL HIGHWAYS AUTHORITY OF INDIA

More information

Key estimate revision. Financial summary. Year FY15 121, % 16, % FY16E 137, % 20,

Key estimate revision. Financial summary. Year FY15 121, % 16, % FY16E 137, % 20, : price: EPS: How does our one year outlook change? We maintain rating on Aurobindo post the company s 3QFY16 results. Revenue growth for the quarter was 10% yoy: US sales of $238mn (vs. estimate of $251mn

More information

Name of the Issue: DLF Limited. Institutional Placement Programme. 1 Type of Issue. 2 Issue Size (Rs. Mn) 18,634.24

Name of the Issue: DLF Limited. Institutional Placement Programme. 1 Type of Issue. 2 Issue Size (Rs. Mn) 18,634.24 Name of the Issue: DLF Limited 1 Type of Issue Institutional Placement Programme 2 Issue Size (Rs. Mn) 18,634.24 Source: Final Post Issue Monitoring Report dated May 27,2013 3 Grade of issue along with

More information

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS RELIANCE HOME FINANCE LIMITED

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS RELIANCE HOME FINANCE LIMITED TRACK RECORD OF THE PUBLIC ISSUES MAGED BY THE MERCHANT BANKER IN THE LAST 3 FINCIAL YEARS RELIANCE HOME FINCE LIMITED 1. Type of Issue Public Issue by Reliance Home Finance ( Company or the Issuer ) of

More information

CMP* (Rs) 840 Upside/ (Downside) (%) (2.4) Bloomberg Ticker Market Cap. (Rs bn) 379 Free Float (%) 53 Shares O/S (mn) 451.6

CMP* (Rs) 840 Upside/ (Downside) (%) (2.4) Bloomberg Ticker Market Cap. (Rs bn) 379 Free Float (%) 53 Shares O/S (mn) 451.6 Event Update November 08, 2017 Market Cap. (Rs bn) 379 Free Float (%) 53 Shares O/S (mn) 451.6 USFDA Warning Letter Entails Further Downside Risk to US Biz The US FDA has issued a Warning Letter (WL) to

More information

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS. India Infoline Finance Limited

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS. India Infoline Finance Limited TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS India Infoline Finance Limited 1. Type of issue Public Issue of Un-Secured Redeemable Non convertible Debentures

More information

Post Issue Performance of Flexituff International Ltd.

Post Issue Performance of Flexituff International Ltd. Post Issue Performance of Flexituff International Ltd. Sr. Particulars No. 1 Name of the issuer Flexituff International Limited ( FIL / the Company ) 2 Type of issue (IPO/ FPO) Initial Public Offer and

More information

BDH Industries Limited BSE Scrip Code:

BDH Industries Limited BSE Scrip Code: BDH Industries Limited BSE Scrip Code: 524828 Pharmaceuticals October 23, 2012 Equity Statistics Current Market Price Rs. 16.95 52 Week High/Low Rs. 21.00/13.15 Market Capitalisation Rs. Crores 9.76 Free

More information

Bird s Eye View of Indian Pharma

Bird s Eye View of Indian Pharma Bird s Eye View of Indian Pharma Classification of Pharma Industry Pharma industry Formulations Active Pharmaceuticals Ingredients Branded Generics Bulk drugs Pfizer Abbott GSK BMS Teva Mylan Dr Reddy

More information

DISCLOSURE OF TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY MERCHANT BANKERS

DISCLOSURE OF TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY MERCHANT BANKERS DISCLOSURE OF TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY MERCHANT BANKERS NAME OF THE ISSUER: INFRASTRUCTURE DEVELOPMENT FINANCE COMPANY LIMITED [since renamed IDFC LIMITED] (TRANCHE 3, FY 2012) Sr.

More information

Aurobindo Pharma Ltd.

Aurobindo Pharma Ltd. . Volume No.. I Issue No. 165 Aurobindo Pharma Ltd. March 12, 2018 BSE Code: 524804 NSE Code: AUROPHARMA Reuters Code: ARBN.NS Bloomberg Code: ARBP:IN Aurobindo Pharma Ltd (Auro) is one of the largest

More information

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS A. For Equity Issues Name of the Mahabir Metallex Limited_SME IPO 1 Type of issue (IPO/ FPO) SME IPO 2 Issue size (Rs crore) Rs. 3.90 crores 3 Grade of issue alongwith name of the rating agency Not Applicable

More information

NATCO PHARMA LTD. Result Update (PARENT BASIS): Q1 FY16

NATCO PHARMA LTD. Result Update (PARENT BASIS): Q1 FY16 ISIN: INE987B01018 OCTOBER 15 th, 2015 STOCK DETAILS Sector NATCO PHARMA LTD. Result Update (PARENT BASIS): Q1 FY16 BSE Code 524816 Face Value 10.00 Pharmaceuticals 52wk. High / Low (Rs.) 2709.00/1245.40

More information

Dr Reddy s Laboratories

Dr Reddy s Laboratories : price: EPS: How does our one year outlook change? We maintain rating on DRRD post the company s 3QFY16 results Revenue growth for the quarter was muted (3% yoy) due to disappointing performances in Russia

More information

Institutional Equities

Institutional Equities 1QFY19 Result Update Institutional Equities Aurobindo Pharma 13 August 2018 Reuters: ARBP.NS; Bloomberg: ARBP IN One-offs Impact Margin Aurobindo Pharma (APL) reported 1QFY19 revenues of Rs42,503mn which

More information

Cadila Healthcare Ltd.

Cadila Healthcare Ltd. Aug-15 Sep-15 Oct-15 Nov-15 Dec-15 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 s. Cadila Healthcare Ltd.. August 8, 216 BSE Code: 532321 NSE Code: CADILAHC Reuters Code: CADI.NS Bloomberg Code:

More information

Aims to achieve the right blend of Growth and Tax Saving

Aims to achieve the right blend of Growth and Tax Saving Aims to achieve the right blend of Growth and Tax Saving DATE OF ALLOTMENT March 31,1996 BENCHMARK S&P BSE Sensex FUND SIZE Rs.981.23 (Rs. in Cr.) MONTHLY AVERAGE AUM Rs.939.37 (Rs. in Cr.) EXIT LOAD Nil

More information

Dec 01, 2016 LAURUS LABS LIMITED. SMC Ranking. (3/5) About the company. Issue Highlights. Strengths. Objects of the Issue. Shareholding Pattern (%)

Dec 01, 2016 LAURUS LABS LIMITED. SMC Ranking. (3/5) About the company. Issue Highlights. Strengths. Objects of the Issue. Shareholding Pattern (%) LAURUS LABS LIMITED Dec 01, 2016 SMC Ranking (3/5) About the company Issue Highlights Industry Pharma Total Issue (Shares) - Offer for sale 24,844,240 Total Issue (Shares) - Fresh Issue 7,009,346 Net Offer

More information

Laurus Labs. Source: Company Data

Laurus Labs. Source: Company Data Strong R&D capabilities, coupled with high debt and WC December 06, 2016 Surajit Pal surajitpal@plindia.com +91 22 66362259 Rating Price Band Subscribe Rs426 428 IPO Fact Sheet Opening Date Dec 06, 2016

More information

Angling for growth. Laurus Labs. Formulation. Synthesis. Ingredients. Hep C API. Oncology API ARV API

Angling for growth. Laurus Labs. Formulation. Synthesis. Ingredients. Hep C API. Oncology API ARV API Initiating Coverage 16 January 2018 Sector: Healthcare Laurus Labs Synthesis Formulation Ingredients Hep C API ARV API Oncology API Angling for growth Tushar Manudhane - Research analyst (Tushar.Manudhane@MotilalOswal.com);

More information

As on September 30, 2009: % of total outstanding capital: 9.20% (includes entire institutional public holding in the company) (2)

As on September 30, 2009: % of total outstanding capital: 9.20% (includes entire institutional public holding in the company) (2) Name of the issue: Adani Power Limited (the Company ) 1. Type of issue (IPO/ FPO) Initial Public Offer (IPO) 2. Issue size (Rs crore) Rs. 3,016.52 crore Source: Final post-issue monitoring report dated

More information

Investor Presentation February 2019

Investor Presentation February 2019 Investor Presentation February 2019 Dr. Reddy s Laboratories Limited Hyderabad, India BSE: 500124 NSE: DRREDDY NYSE: RDY Safe Harbor Statement This presentation contains forward-looking statements and

More information

CMP* (Rs) 417 Upside/ (Downside) (%) 46 Bloomberg Ticker. SUNP IN Market Cap. (Rs bn) 1,001 Free Float (%) 46 Shares O/S (mn) 2399

CMP* (Rs) 417 Upside/ (Downside) (%) 46 Bloomberg Ticker. SUNP IN Market Cap. (Rs bn) 1,001 Free Float (%) 46 Shares O/S (mn) 2399 Company Update January 22, 2019 Market Cap. (Rs bn) 1,001 Free Float (%) 46 Shares O/S (mn) 2399 Multiple Growth Drivers in Place despite Near-term Headwinds Industries (SUNP) has released an investor

More information

Institutional Equities

Institutional Equities Company Update Institutional Equities Dr. Reddy s Laboratories 5 September 2017 Reuters: REDY.BO; Bloomberg: DRRD IN Suboxone Generic Opportunity To Be Lucrative, Can Sustain For Longer Time The district

More information

Gillette India. Institutional Equities. 2QFY19 Result Update BUY. Marketing Investments Mask Improved Top-line Performance

Gillette India. Institutional Equities. 2QFY19 Result Update BUY. Marketing Investments Mask Improved Top-line Performance 2QFY19 Result Update Gillette India 13 February 2019 Reuters: GILE.NS; Bloomberg: GILL IN Marketing Investments Mask Improved Top-line Performance Gillette India s (GILL) 2QFY19 operating and net earnings

More information

BUY CMP (Rs.) 297 Target (Rs.) 385 Potential Upside 30%

BUY CMP (Rs.) 297 Target (Rs.) 385 Potential Upside 30% Nov-15 Dec-15 Jan-16 Feb-16 Mar-16 Apr-16 May- Jun-16 Jul-16 Aug-16 Aug-16 Sep-16 Oct-16. Volume No.. I Issue No. 95 Dewan Housing Finance Corporation (DHFL) Nov. 4, 2016 BSE Code: 511072 NSE Code: DHFL

More information

MCX Ltd. Rating: Target price: EPS: Tepid volume growth continues. Target. Rating CMP. Rs. 1,080 SELL. Rs. 1,176

MCX Ltd. Rating: Target price: EPS: Tepid volume growth continues. Target. Rating CMP. Rs. 1,080 SELL. Rs. 1,176 : price: EPS: Tepid volume growth continues 4QFY15 traded volumes in MCX showed a small improvement sequentially whereas declined yoy. FY15 traded Values are at a sever year low. We retain our cautious

More information

Motilal Oswal MidCap 100 ETF

Motilal Oswal MidCap 100 ETF Motilal Oswal MidCap 100 ETF Product labeling This product is suitable for investors who are seeking* Return that corresponds generally to the performance of the NIFTY Midcap 100 index, subject to tracking

More information

Institutional Equities

Institutional Equities 1QFY19 Result Update Institutional Equities Dr. Reddy s Laboratories 27 July 2018 Reuters: REDY.BO; Bloomberg: DRRD IN Drug Pipeline In Place, But Regulatory Hurdles Testing Patience Dr. Reddy s Laboratories

More information

CMP* (Rs) 1,033 Upside/ (Downside) (%) (0.3) Bloomberg Ticker Market Cap. (Rs bn) 467 Free Float (%) 53 Shares O/S (mn) 452

CMP* (Rs) 1,033 Upside/ (Downside) (%) (0.3) Bloomberg Ticker Market Cap. (Rs bn) 467 Free Float (%) 53 Shares O/S (mn) 452 2QFY18 Result Update October 31, 2017 Market Cap. (Rs bn) 467 Free Float (%) 53 Shares O/S (mn) 452 US Biz to Remain Weak; Maintain Led by weak performance in the US markets, (LPC) has delivered a weak

More information

Colgate-Palmolive (India)

Colgate-Palmolive (India) Result Update Colgate-Palmolive (India) 27 July 218 Reuters: COLG.BO; Bloomberg: CLGT IN Tough Times Continue Colgate-Palmolive (India) or CLGT reported a mixed earnings performance in. Volume and revenue

More information

Aurobindo Pharma. Institutional Equity Research. Sector - Pharmaceuticals. RSec TradEdge India. March 02, 2017

Aurobindo Pharma. Institutional Equity Research. Sector - Pharmaceuticals. RSec TradEdge India. March 02, 2017 Recommendation Range STOP LOSS Target 678 638 765 Aurobindo Pharma Sector - Pharmaceuticals Background & Business Aurobindo Pharma (ARBP) is a mid-sized Indian pharma company with one of the largest product

More information

ALEMBIC PHARMACEUTICALS LTD.(APL)

ALEMBIC PHARMACEUTICALS LTD.(APL) ALEMBIC PHARMACEUTICALS LTD.(APL) Date : 13 th September, 212 Stock Performance Details Current Price : Rs. 73.35** Face Value : Rs. 2 per share 52 wk High / Low : Rs. 78.95 / Rs.34. Total Traded Volumes

More information

MCX Ltd. Rating: Target price: EPS: Is commodity option a game changer for MCX? - Unlikely. Target. Rating CMP. Rs. 1,080 SELL. Rs.

MCX Ltd. Rating: Target price: EPS: Is commodity option a game changer for MCX? - Unlikely. Target. Rating CMP. Rs. 1,080 SELL. Rs. : price: EPS: Is commodity option a game changer for MCX? - Unlikely In the union budget 2015-16, the Finance Minister announced the much anticipated merger of SEBI and FMC. Given the powers accorded to

More information

J.B. Chemicals & Pharmaceuticals Ltd.

J.B. Chemicals & Pharmaceuticals Ltd. Oct-16 Nov-16 Nov-16 Dec-16 Jan-17 Jan-17 Feb-17 Mar-17 Apr-17 Apr-17 May-17 Jun-17 Jun-17 Jul-17 Aug-17 Aug-17 Sep-17 Oct-17. Volume No.. I Issue No. 146 J.B. Chemicals & Pharmaceuticals Ltd. October

More information

INVESTMENT RESEARCH FUNDAMENTAL COVERAGE - SEQUENT SCIENTIFIC LIMITED. Future Strategy

INVESTMENT RESEARCH FUNDAMENTAL COVERAGE - SEQUENT SCIENTIFIC LIMITED. Future Strategy Future Strategy INVESTMENT RESEARCH Dated : 09th Nov. 2017 Price ` 100 Fair Value 130 Upside 30% Div Yield - Tenure 1 YEAR Sensex 33250.93 Nifty 10308.95 Group/Index B / S&P BSE 500 M.cap (` in cr) 2438

More information

CMP (Rs) 775 Upside/ (Downside) (%) (1.4) Market Cap. (Rs bn) 11.4 Free Float (%) 35.0 Shares O/S (mn) 14.7

CMP (Rs) 775 Upside/ (Downside) (%) (1.4) Market Cap. (Rs bn) 11.4 Free Float (%) 35.0 Shares O/S (mn) 14.7 2QFY18 Result Update November 23, 2017 Market Cap. (Rs bn) 11.4 Free Float (%) 35.0 Shares O/S (mn) 14.7 High Order Book Provides Revenue Visibility (PMPL) has delivered a healthy performance in 2QFY18.

More information

NATIONAL STOCK EXCHANGE OF INDIA BSE LIMITED Phiroz Jeejeebhoy Towers, Exchange Plaza,

NATIONAL STOCK EXCHANGE OF INDIA BSE LIMITED Phiroz Jeejeebhoy Towers, Exchange Plaza, (? AUROBINDO Date: November 12, 2018 To To NATIONAL STOCK EXCHANGE OF INDIA BSE LIMITED LIMITED Phiroz Jeejeebhoy Towers, Exchange Plaza, 25 th floor, Dalal Street, Sandra Kurla Complex, Sandra (E), MUMBAI

More information

Financials/Valuation. 1Mn 3Mn 1Yr P/B (X) Absolute (7.8) (6.3) (5.3) P/E (x) Rel.to Nifty (6.5) (8.6) (25.0) Recent Developments:

Financials/Valuation. 1Mn 3Mn 1Yr P/B (X) Absolute (7.8) (6.3) (5.3) P/E (x) Rel.to Nifty (6.5) (8.6) (25.0) Recent Developments: Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 Jan-18 Feb-18 08-Feb-18 Bloomberg- INDUSTRY - CIPLA IN BSE Code - 500087 NSE Code - NIFTY - PHARMACEUTICAL CIPLA 10476 Comapany

More information

Dalmia Bharat Enterprises

Dalmia Bharat Enterprises Result Update Dalmia Bharat Enterprises 1 November 218 Reuters: DALA.BO; Bloomberg: DBEL IN Performance In Line; Stock Under Review Post Odisha Cement Amalgamation Dalmia Bharat Enterprises (DBEL) reported

More information

Reliance Focused Large Cap Fund

Reliance Focused Large Cap Fund Reliance Focused Large Cap Fund Formerly, Reliance Equity Fund (An open ended Diversified Equity Scheme) To know more call us at 1800 300 11111 visit www.reliancemutual.com Download Free App Download with

More information

HDFC Bank. BUY CMP (Rs.) 1,807 Target (Rs.) 2,000 Potential Upside 11%

HDFC Bank. BUY CMP (Rs.) 1,807 Target (Rs.) 2,000 Potential Upside 11% Oct-16 Nov-16 Dec-16 Jan-17 Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17. Volume No.. I Issue No. 147 HDFC Bank Oct. 31, 2017 BSE Code: 500180 NSE Code: HDFCBANK Reuters Code: HDBK.NS

More information

Religare Invesco Mid N Small Cap Fund

Religare Invesco Mid N Small Cap Fund Religare Invesco Mid N Small Cap Fund An Open Ended Equity Scheme Suitable for investors who are seeking*: Capital appreciation over long term Investment predominantly in equity and equityrelated instruments

More information

Investor Presentation

Investor Presentation Investor Presentation Q3 FY 15 Earnings Release 12 Feb 2015 Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute

More information

Alkem Labs BUY RESULTS REVIEW 1QFY19 11 AUG story remains on-track. Maintain BUY with a revised TP of Rs 2,410 (24x FY20E EPS).

Alkem Labs BUY RESULTS REVIEW 1QFY19 11 AUG story remains on-track. Maintain BUY with a revised TP of Rs 2,410 (24x FY20E EPS). INDUSTRY PHARMA CMP (as on 10 Aug 2018) Rs 2,060 Target Price Rs 2,410 Nifty 11,430 Sensex 37,869 KEY STOCK DATA Bloomberg ALKEM IN No. of Shares (mn) 120 MCap (Rs bn) / ($ mn) 246/3,576 6m avg traded

More information

PEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)

PEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%) BUY CMP 608.85 Target Price 694.00 CIPLA LIMITED Result Update (PARENT BASIS): Q2 FY15 NOVEMBER 18 th,2014 ISIN: INE059A01026 Index Details Stock Data Sector Pharmaceuticals BSE Code 500087 Face Value

More information

Product Labeling. Investment in equity securities of NIFTY Midcap 100 index

Product Labeling. Investment in equity securities of NIFTY Midcap 100 index Title slide Product Labeling This product is suitable for investors who are seeking* Return that corresponds generally to the performance of the NIFTY Midcap 100 index, subject to tracking error. Investment

More information

Sun Pharmaceutical Industries

Sun Pharmaceutical Industries Event Update Institutional Equities Sun Pharmaceutical Industries Reuters: SUN.BO; Bloomberg: SUNP IN Surprise Audit Of Halol Unit By USFDA - Outcome Is Key As per a report in the Business Standard newspaper

More information

Participate in one of the key drivers of Growth & Development in India

Participate in one of the key drivers of Growth & Development in India Participate in one of the key drivers of Growth & Development in India DATE OF ALLOTMENT December 28, 2015 BENCHMARK Nifty Financial Services TRI (WEF From 1st February 2018) FUND SIZE Rs.261.73 (Rs. in

More information

Formulations Performance Highlights Q3 FY18

Formulations Performance Highlights Q3 FY18 Press Release Strides announces Q3 FY18 results Continuing adjusted EBITDA at INR 1,441 Mn Revenues* at INR 7,536 Mn Adjusted PAT* at INR 630 Mn (* for continuing business) Bengaluru, February 9, 2018:

More information

CMP* (Rs) 166 Upside/ (Downside) (%) 28 Bloomberg Ticker. NTPC IN Market Cap. (Rs bn) 1,361 Free Float (%) 37.7 Shares O/S (mn) 8,245

CMP* (Rs) 166 Upside/ (Downside) (%) 28 Bloomberg Ticker. NTPC IN Market Cap. (Rs bn) 1,361 Free Float (%) 37.7 Shares O/S (mn) 8,245 3QFY18 Result Update February 05, 2018 CMP* (Rs) 166 Market Cap. (Rs bn) 1,361 Free Float (%) 37.7 Shares O/S (mn) 8,245 Wage Provisioning, Lower in Plant Availability Impede Earnings Growth has delivered

More information

ITC. Institutional Equities. 4QFY18 Result Update. Tracking Expectations ACCUMULATE. Sector: FMCG CMP: Rs286 Target Price: Rs290 Upside: 1%

ITC. Institutional Equities. 4QFY18 Result Update. Tracking Expectations ACCUMULATE. Sector: FMCG CMP: Rs286 Target Price: Rs290 Upside: 1% 4QFY18 Result Update Institutional Equities ITC 17 May 2018 Reuters: ITC.NS; Bloomberg: ITC IN Tracking Expectations ITC s growth in 4QFY18 was modest and in line with expectations. On the revenue side,

More information

NESCO. Institutional Equities. Event Update. Revenues From Bombay Exhibition Centre May Take A Hit BUY

NESCO. Institutional Equities. Event Update. Revenues From Bombay Exhibition Centre May Take A Hit BUY Event Update Institutional Equities NESCO 27 August 2018 Reuters: NSEN.NS; Bloomberg: NSE IN Revenues From Bombay Exhibition Centre May Take A Hit This event update relates to an application made on 14

More information

Reduce. Punjab National Bank Banking RETAIL EQUITY RESEARCH. Not out of the woods. GEOJIT BNP PARIBAS Research. 10 th August 2016 Q1FY17 RESULT UPDATE

Reduce. Punjab National Bank Banking RETAIL EQUITY RESEARCH. Not out of the woods. GEOJIT BNP PARIBAS Research. 10 th August 2016 Q1FY17 RESULT UPDATE Q1FY17 RESULT UPDATE Aug-15 Sep-15 Oct-15 GEOJIT BNP PARIBAS Research Nov-15 Dec-15 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 RETAIL EQUITY RESEARCH Punjab National Bank Banking BSE CODE:

More information

Dividend Report. December 2018

Dividend Report. December 2018 Warning: Aberdeen Global has the discretion to determine the and rate of dividend to be distributed. The dividends are not guaranteed and may be investment income, gains or at the discretion of the Board

More information

Divi's Laboratories (Divi's)

Divi's Laboratories (Divi's) Divi's Laboratories (Divi's) Institutional Equity Research Pharma India DIVI IN; DIVI.BO November 3, 2014 2QF15 result review HOLD Weak F15 + Full valuation = Downgrade to Hold Current price (31 Oct) Rs

More information

Percentage (%) 9.05% 19.24% 20.66% 20.93% 21.87% N.A.

Percentage (%) 9.05% 19.24% 20.66% 20.93% 21.87% N.A. Name the Issuer POWER GRID CORPORATION OF INDIA LIMITED 1 Type issue (IPO/ FPO) FPO 2 Issue size (Rs crore) 7,442.34* *includes Offer for Sale Rs.3,713.94 Crore 3 Grade issue alongwith name the rating

More information

Karur Vysya Bank (KVB) KVB IN; KVB.BO

Karur Vysya Bank (KVB) KVB IN; KVB.BO Banking India (KVB) KVB IN; KVB.BO Institutional Equity Research May 2, 2015 result review HOLD Consolidating growth, high capital, elevated slippages Current price (30 Apr) Rs 482 Target price Rs 560

More information

Jamna Auto Industries

Jamna Auto Industries 2QFY19 Result Update Institutional Equities Jamna Auto Industries Reuters: JMNA.NS; Bloomberg: JMNA IN Performance Below Expectations; Retain Buy Due To Strong Outlook Jamna Auto s 2QFY19 earnings were

More information

PEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)

PEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%) BUY CMP 940.00 Target Price 1080.00 TTK HEALTHCARE LTD Result Update (PARENT BASIS): Q2 FY16 DECEMBER 10 th 2015 ISIN: INE910C01018 Index Details Stock Data Sector Pharmaceuticals BSE Code 507747 Face

More information

Institutional Equities

Institutional Equities 4QFY18 Result Update Institutional Equities Atul Auto 30 May 2018 Reuters: ATUL.BO; Bloomberg: ATUL IN Higher Expenses Mar Profitability Atul Auto s (AAL) 4QFY18 earnings missed our expectations on account

More information